

# Dharmarajan Sriram

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2380258/publications.pdf>

Version: 2024-02-01

189  
papers

4,954  
citations

94433

37  
h-index

175258

52  
g-index

189  
all docs

189  
docs citations

189  
times ranked

5442  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aryl-n-hexanamide linked enamines of usnic acid as promising antimicrobial agents. <i>Molecular Diversity</i> , 2023, 27, 811-836.	3.9	3
2	Novel fluoroquinolones containing 2-arylamino-2-oxoethyl fragment: Design, synthesis, evaluation of antibacterial and antituberculosis activities and molecular modeling studies. <i>Journal of Heterocyclic Chemistry</i> , 2022, 59, 909-926.	2.6	9
3	Synthesis and biological evaluation of isatin oxime ether-tethered aryl 1 <i>H</i> -1,2,3-triazoles as inhibitors of <i>Mycobacterium tuberculosis</i> . <i>New Journal of Chemistry</i> , 2022, 46, 2863-2874.	2.8	12
4	Indole-2-carboxamides as New Anti-Mycobacterial Agents: Design, Synthesis, Biological Evaluation and Molecular Modeling against mmpL3. <i>ChemistrySelect</i> , 2022, 7, .	1.5	7
5	Indole-fused spirochromenes as potential anti-tubercular agents: design, synthesis and in vitro evaluation. <i>Molecular Diversity</i> , 2021, 25, 2137-2148.	3.9	13
6	Synthesis and antimicrobial evaluation of new nitric oxide-donating fluoroquinolone/oxime hybrids. <i>Archiv Der Pharmazie</i> , 2021, 354, e2000180.	4.1	11
7	Design and characterisation of piperazine-benzofuran integrated dinitrobenzenesulfonamide as <i>Mycobacterium tuberculosis</i> H37Rv strain inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1751-1759.	5.2	6
8	Sacubitril-Based Urea and Thiourea Derivatives as Novel Inhibitors for Anti-Tubercular against Dormant <i>Mycobacterium tuberculosis</i> . <i>ChemistrySelect</i> , 2021, 6, 3869-3874.	1.5	16
9	Stereoselective synthesis and discovery of novel spirooxindolopyrrolidine engrafted indandione heterocyclic hybrids as antimycobacterial agents. <i>Bioorganic Chemistry</i> , 2021, 110, 104798.	4.1	20
10	3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents. <i>Archiv Der Pharmazie</i> , 2021, 354, e2000419.	4.1	4
11	Antihypernociceptive effects of <i>Petersianthus macrocarpus</i> stem bark on neuropathic pain induced by chronic constriction injury in rats. <i>Inflammopharmacology</i> , 2021, 29, 1241-1253.	3.9	2
12	e-Pharmacophore model-guided design of potential DprE1 inhibitors: synthesis, in vitro antitubercular assay and molecular modelling studies. <i>Chemical Papers</i> , 2021, 75, 5571-5585.	2.2	6
13	Lead derivatization of ethyl 6-bromo-2-((dimethylamino)methyl)-5-hydroxy-1-phenyl-1 <i>H</i> -indole-3-carboxylate and 5-bromo-2-(thiophene-2-carboxamido) benzoic acid as FabG inhibitors targeting ESKAPE pathogens. <i>European Journal of Medicinal Chemistry</i> , 2021, 113, 113976.	5.5	1
14	Synthesis and bioevaluation of 1,1'-bis(1 <i>H</i> -1,2,3-triazol-5-ylmethylene) ketones. <i>Chemical Papers</i> , 2020, 74, 809-820.	2.2	5
15	Discovery of hydrazone containing thiadiazoles as <i>Mycobacterium tuberculosis</i> growth and enoyl acyl carrier protein reductase (InhA) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 112035.	5.5	26
16	Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents. <i>Journal of Natural Products</i> , 2020, 83, 26-35.	3.0	50
17	Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles. <i>Synthetic Communications</i> , 2020, 50, 271-288.	2.1	17
18	Design and synthesis of purine connected piperazine derivatives as novel inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127512.	2.2	23

#	ARTICLE	IF	CITATIONS
19	Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127579.	2.2	24
20	1,3-Disubstituted urea derivatives: Synthesis, antimicrobial activity evaluation and in silico studies. <i>Bioorganic Chemistry</i> , 2020, 102, 104104.	4.1	22
21	Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]ones and their antituberculosis and anticancer activity. <i>Archiv Der Pharmazie</i> , 2020, 353, 2000192.	4.1	8
22	Novel isoniazid embedded triazole derivatives: Synthesis, antitubercular and antimicrobial activity evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127434.	2.2	31
23	Pyrazole-coumarin and pyrazole-quinoline chalcones as potential antitubercular agents. <i>Archiv Der Pharmazie</i> , 2020, 353, e2000077.	4.1	36
24	Design, synthesis and biological evaluation of novel <i>Pseudomonas aeruginosa</i> DNA gyrase B inhibitors. <i>Bioorganic Chemistry</i> , 2020, 100, 103905.	4.1	5
25	Synthesis of novel 5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline-6-carboxamides as potent inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Monatshefte Für Chemie</i> , 2020, 151, 405-415.	1.8	1
26	Synthesis of isoniazid-1,2,3-triazole conjugates: Antitubercular, antimicrobial evaluation and molecular docking study. <i>Journal of Heterocyclic Chemistry</i> , 2020, 57, 3544-3557.	2.6	14
27	Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as <i>Mycobacterium tuberculosis</i> ketol-acid reductoisomerase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 193, 112178.	5.5	12
28	Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127037.	2.2	7
29	Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies. <i>Bioorganic Chemistry</i> , 2020, 96, 103610.	4.1	38
30	Synthesis, in vitro, and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides. <i>Bioorganic Chemistry</i> , 2020, 96, 103626.	4.1	12
31	Anti-tubercular activity of novel class of spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids. <i>Bioorganic Chemistry</i> , 2020, 99, 103799.	4.1	24
32	Design and synthesis of thiourea-based derivatives as <i>Mycobacterium tuberculosis</i> growth and enoyl acyl carrier protein reductase (InhA) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 199, 112402.	5.5	27
33	Regio- and diastereoselective synthesis of spiropyrroloquinoxaline grafted indole heterocyclic hybrids and evaluation of their anti- <i>Mycobacterium tuberculosis</i> activity. <i>RSC Advances</i> , 2020, 10, 23522-23531.	3.6	21
34	5-Chloro-2-thiophenyl-1,2,3-triazolymethyl-dihydroquinolines as dual inhibitors of <i>Mycobacterium tuberculosis</i> and influenza virus: Synthesis and evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2664-2669.	2.2	9
35	Design and Synthesis of New Aryloxy-linked Dimeric 1,2,3-Triazoles via Click Chemistry Approach: Biological Evaluation and Molecular Docking Study. <i>Journal of Heterocyclic Chemistry</i> , 2019, 56, 2144-2162.	2.6	15
36	Synthesis of Disulfide-Bridged N-Phenyl-N-(alkyl/aryl/heteroaryl)urea Derivatives and Evaluation of Their Antimicrobial Activities. <i>Chemistry and Biodiversity</i> , 2019, 16, e1900461.	2.1	2

#	ARTICLE	IF	CITATIONS
37	Discovery and evaluation of novel Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors as therapeutic drug leads. <i>Journal of Computer-Aided Molecular Design</i> , 2019, 33, 357-366.	2.9	38
38	New fluoroquinolones/nitric oxide donor hybrids: design, synthesis and antitubercular activity. <i>Medicinal Chemistry Research</i> , 2019, 28, 1272-1283.	2.4	9
39	Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 315-328.	5.5	30
40	Targeting HIV&TB coinfection by developing novel piperidin&substituted imines: Design, synthesis, in vitro and in silico studies. <i>Archiv Der Pharmazie</i> , 2019, 352, 1800358.	4.1	4
41	Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles. <i>Synthetic Communications</i> , 2019, 49, 2017-2028.	2.1	41
42	Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents. <i>Bioorganic Chemistry</i> , 2019, 88, 102965.	4.1	19
43	Ultrasonication-ionic liquid synergy for the synthesis of new potent anti-tuberculosis 1,2,4-triazol-1-yl-pyrazole based spirooxindolopyrrolizidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1682-1687.	2.2	42
44	Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis. <i>Future Medicinal Chemistry</i> , 2019, 11, 499-510.	2.3	26
45	Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1421-1429.	3.0	13
46	The design and green synthesis of novel benzotriazoloquinolinyl spirooxindolopyrrolizidines: antimycobacterial and antiproliferative studies. <i>New Journal of Chemistry</i> , 2019, 43, 17511-17520.	2.8	17
47	Synthesis of novel morpholine, thiomorpholine and N-substituted piperazine coupled 2-(thiophen-2-yl)dihydroquinolines as potent inhibitors of Mycobacterium tuberculosis. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 171-178.	5.5	23
48	Synthesis and evaluation of $\pm$ -aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 665-677.	5.5	20
49	Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 284-290.	2.2	41
50	Synthesis and evaluation of novel substituted 1,2,3-triazolyldihydroquinolines as promising antitubercular agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 529-533.	2.2	23
51	Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety as Potential Antimycobacterial Agents. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2019, 16, 432-436.	1.4	5
52	In silico design of small peptides antagonist against leptin receptor for the treatment of obesity and its associated immune-mediated diseases. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 82, 20-36.	2.4	12
53	Design, Synthesis, and in vitro antitubercular activity of 1,2,3&triazolyldihydroquinoline derivatives. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1315-1323.	3.2	5
54	Synthesis and evaluation of 4&2,5&2-dihydrospiro[piperidine-4,7&2-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1462-1469.	3.0	12

#	ARTICLE	IF	CITATIONS
55	Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 23-34.	5.5	26
56	Dibenzofuran, dibenzothiophene and N-methyl carbazole tethered 2-aminothiazoles and their cinnamamides as potent inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1610-1614.	2.2	20
57	Discovery of novel inhibitors of <i>Mycobacterium tuberculosis</i> MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 3184-3198.	3.5	40
58	Lead identification and optimization of bacterial glutamate racemase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 177-190.	3.0	10
59	Rational design of coumarin derivatives as antituberculosis agents. <i>Future Medicinal Chemistry</i> , 2018, 10, 2431-2444.	2.3	8
60	Clickable conjugates of bile acids and nucleosides: Synthesis, characterization, in vitro anticancer and antituberculosis studies. <i>Steroids</i> , 2018, 139, 35-44.	1.8	19
61	Structure-based design of some isonicotinic acid hydrazide analogues as potential antitubercular agents. <i>Bioorganic Chemistry</i> , 2018, 80, 721-732.	4.1	14
62	Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair <i>M. smegmatis</i> Growth and Disturb Chromosome Replication. <i>Frontiers in Microbiology</i> , 2018, 9, 1592.	3.5	24
63	Identification and development of novel indazole derivatives as potent bacterial peptidoglycan synthesis inhibitors. <i>International Journal of Mycobacteriology</i> , 2018, 7, 76.	0.6	3
64	Layer-by-Layer Thin Films for Co-Delivery of TGF- $\beta$ 2 siRNA and Epidermal Growth Factor to Improve Excisional Wound Healing. <i>AAPS PharmSciTech</i> , 2017, 18, 809-820.	3.3	29
65	Polymer-gold nanoparticle composite films for topical application: Evaluation of physical properties and antibacterial activity. <i>Polymer Composites</i> , 2017, 38, 2829-2840.	4.6	14
66	A Facile Synthesis and Antituberculosis Properties of Almazole D and Its Enantiomer. <i>ChemistrySelect</i> , 2017, 2, 1250-1252.	1.5	12
67	A robust synthesis of functionalized 2 H-indazoles via solid state melt reaction (SSMR) and their anti-tubercular activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1593-1597.	2.2	30
68	Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as <i>Mycobacterium tuberculosis</i> gyrase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1859-1866.	2.2	18
69	Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,3,4-oxadiazole derivatives. <i>Chemical Biology and Drug Design</i> , 2017, 90, 496-500.	3.2	8
70	Inhibition of tyrosinase by 4 H-chromene analogs: Synthesis, kinetic studies, and computational analysis. <i>Chemical Biology and Drug Design</i> , 2017, 90, 804-810.	3.2	15
71	<i>Mycobacterium tuberculosis</i> lysine- $\epsilon$ -aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2761-2771.	3.0	25
72	Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2-c]pyridine Mannich bases. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 275-288.	5.5	25

#	ARTICLE	IF	CITATIONS
73	Synthesis and anti-mycobacterial activity of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)salicylhydrazones: revitalizing an old drug. <i>Archives of Pharmacal Research</i> , 2017, 40, 168-179.	6.3	15
74	Novel Zebrafish EAE model: A quick in vivo screen for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 32-39.	2.0	28
75	Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2- b ]pyridine-1,2,3-triazole derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5119-5121.	2.2	38
76	Correlation of pharmacokinetics and brain penetration data of adult zebrafish with higher mammals including humans. <i>Journal of Pharmacological and Toxicological Methods</i> , 2017, 88, 147-152.	0.7	8
77	Bis-spirochromanones as potent inhibitors of <i>Mycobacterium tuberculosis</i> : synthesis and biological evaluation. <i>Molecular Diversity</i> , 2017, 21, 999-1010.	3.9	7
78	Profiling of in vitro activities of urea-based inhibitors against cysteine synthases from <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4582-4587.	2.2	13
79	Synthesis, crystal structure and antimycobacterial activities of 4-indolyl-1,4-dihydropyridine derivatives possessing various ester groups. <i>Research on Chemical Intermediates</i> , 2017, 43, 7471-7489.	2.7	10
80	Inhibitors of the Cysteine Synthase CysM with Antibacterial Potency against Dormant <i>Mycobacterium tuberculosis</i> . <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6848-6859.	6.4	45
81	Design and Development of <i>Mycobacterium tuberculosis</i> Lysine $\epsilon$ -Aminotransferase Inhibitors for Latent Tuberculosis Infection. <i>Chemical Biology and Drug Design</i> , 2016, 87, 265-274.	3.2	8
82	Design and development of novel inhibitors for the treatment of latent tuberculosis. <i>International Journal of Mycobacteriology</i> , 2016, 5, S121-S122.	0.6	2
83	Synthesis, biological evaluation and structure-activity relationship of 2-styrylquinazolones as anti-tubercular agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2663-2669.	2.2	49
84	Click-based synthesis and antitubercular evaluation of novel dibenzo[ b , d ]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2649-2654.	2.2	34
85	Synthesis and antitubercular evaluation of novel dibenzo[ b , d ]thiophene tethered imidazo[1,2- a ]pyridine-3-carboxamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3135-3140.	2.2	22
86	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3- d ]pyrimidin-4-amine analogues endowed with high activity toward non-replicative <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5556-5564.	3.0	9
87	Design and development of new class of <i>Mycobacterium tuberculosis</i> l-alanine dehydrogenase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4499-4508.	3.0	12
88	A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4292-4295.	2.2	25
89	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 216-231.	5.5	28
90	Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3684-3689.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 877-885.	3.0	19
92	Energy-Based Pharmacophore and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling Combined with Virtual Screening To Identify Novel Small-Molecule Inhibitors of Silent Mating-Type Information Regulation 2 Homologue 1 (SIRT1). <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 173-187.	5.4	20
93	Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 42-52.	3.0	8
94	Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1298-1307.	3.0	49
95	Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2562-2568.	2.2	32
96	Ionic liquid-promoted one-pot synthesis of thiazole-imidazo[2,1-b][1,3,4]thiadiazole hybrids and their antitubercular activity. <i>MedChemComm</i> , 2016, 7, 338-344.	3.4	20
97	Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. <i>Steroids</i> , 2016, 107, 87-97.	1.8	29
98	Synthesis of new pyrazole-triazole hybrids by click reaction using a green solvent and evaluation of their antitubercular and antibacterial activity. <i>Research on Chemical Intermediates</i> , 2016, 42, 3721-3741.	2.7	22
99	Synthesis of novel 5-[(1,2,3-triazol-4-yl)methyl]-1-methyl-3H-pyridazo[4,5-b]indol-4-one derivatives by click reaction and exploration of their anticancer activity. <i>Medicinal Chemistry Research</i> , 2016, 25, 135-148.	2.4	13
100	Structural Models for the Design of PKMzeta Inhibitors with Neurobiological Indications. <i>Molecular Informatics</i> , 2015, 34, 665-678.	2.5	1
101	New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2768-2772.	2.2	43
102	Design and development of novel Mycobacterium tuberculosis l-alanine dehydrogenase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 401-414.	5.5	31
103	Design and Biological Evaluation of Furan/Pyrrrole/Thiophene-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of <i>Staphylococcus aureus</i> . <i>Chemical Biology and Drug Design</i> , 2015, 86, 918-925.	3.2	15
104	Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 415-426.	5.5	30
105	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1402-1412.	3.0	20
106	Synthesis, in vitro anticancer and antimycobacterial evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1398-1402.	2.2	44
107	A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture. <i>Virology Journal</i> , 2015, 12, 16.	3.4	42
108	Design of novel dispirooxindolopyrrolidine and dispirooxindolopyrrolothiazole derivatives as potential antitubercular agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4308-4313.	2.2	35

#	ARTICLE	IF	CITATIONS
109	Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors. International Journal of Mycobacteriology, 2015, 4, 104-115.	0.6	25
110	Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase. Journal of Molecular Graphics and Modelling, 2015, 60, 124-131.	2.4	16
111	Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis. European Journal of Pharmaceutical Sciences, 2015, 72, 81-92.	4.0	13
112	Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives. European Journal of Medicinal Chemistry, 2015, 95, 49-63.	5.5	74
113	Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening. Chemical Biology and Drug Design, 2015, 86, 881-894.	3.2	13
114	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 2062-2078.	3.0	45
115	Discovery of novel lysine $\epsilon$ -aminotransferase inhibitors: An intriguing potential target for latent tuberculosis. Tuberculosis, 2015, 95, 786-794.	1.9	14
116	Pyridoxal-phosphate dependent mycobacterial cysteine synthases: Structure, mechanism and potential as drug targets. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 1175-1183.	2.3	28
117	One-pot synthesis of new triazole-imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4169-4173.	2.2	54
118	Antinociceptive properties of the aqueous and methanol extracts of the stem bark of Petersianthus macrocarpus (P. Beauv.) Liben (Lecythidaceae) in mice. Journal of Ethnopharmacology, 2015, 174, 66-73.	4.1	13
119	Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 485-491.	2.2	39
120	Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: Hit to lead optimization of a novel class of thiazole inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 588-601.	3.0	20
121	Rational design, synthesis and evaluation of novel-substituted 1,2,3-triazolylmethyl carbazoles as potent inhibitors of Mycobacterium tuberculosis. Medicinal Chemistry Research, 2015, 24, 1298-1309.	2.4	29
122	Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives. European Journal of Medicinal Chemistry, 2015, 89, 616-627.	5.5	20
123	Depletion of M. tuberculosis GlmU from Infected Murine Lungs Effects the Clearance of the Pathogen. PLoS Pathogens, 2015, 11, e1005235.	4.7	35
124	A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells <i>In Vitro</i>. Cancer Research and Treatment, 2015, 47, 913-920.	3.0	6
125	Salicylanilide Diethyl Phosphates as Potential Inhibitors of Some Mycobacterial Enzymes. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	7
126	Discovery of Novel Mycobacterial DNA Gyrase B Inhibitors: In Silico and In Vitro Biological Evaluation. Molecular Informatics, 2014, 33, 597-609.	2.5	15



#	ARTICLE	IF	CITATIONS
127	Anti-mycobacterial, cytotoxic activities of Knoevenagel and (E)- $\beta$ , $\beta$ -unsaturated esters and ketones from 2-chloronicotinaldehydes. <i>Medicinal Chemistry Research</i> , 2014, 23, 199-206.	2.4	7
128	Development of antimycobacterial tetrahydrothieno[2,3-c]pyridine-3-carboxamides and hexahydrocycloocta[b]thiophene-3-carboxamides: Molecular modification from known antimycobacterial lead. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 110-117.	5.5	9
129	Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: Scaffold hopping from known antibacterial leads. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 269-278.	2.5	29
130	Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based <i>Mycobacterium tuberculosis</i> pantothenate synthetase inhibitors: Molecular hybridization from known antimycobacterial leads. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1938-1947.	3.0	31
131	Synthesis and antimycobacterial activities of some new thiazolylhydrazone derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1695-1697.	2.2	23
132	Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1974-1979.	2.2	27
133	Discovery of tetrahydropyrido[4,3-d]pyrimidine derivatives for the treatment of neuropathic pain. <i>Bioorganic Chemistry</i> , 2014, 52, 69-76.	4.1	8
134	Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 333-339.	5.5	28
135	Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of <i>Mycobacterium tuberculosis</i> . <i>European Journal of Medicinal Chemistry</i> , 2014, 71, 160-167.	5.5	50
136	Identification of novel inhibitors against <i>Mycobacterium tuberculosis</i> l-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening. <i>Journal of Molecular Graphics and Modelling</i> , 2014, 47, 37-43.	2.4	36
137	Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 233-236.	2.2	44
138	Synthesis of novel dispiropyrrrolothiazoles by three-component 1,3-dipolar cycloaddition and evaluation of their antimycobacterial activity. <i>RSC Advances</i> , 2014, 4, 59462-59471.	3.6	33
139	An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for <i>Mycobacterium tuberculosis</i> DNA GyrB inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6552-6563.	3.0	38
140	Optimization and validation of <i>Mycobacterium marinum</i> -induced adult zebrafish model for evaluation of oral anti-tuberculosis drugs. <i>International Journal of Mycobacteriology</i> , 2014, 3, 259-267.	0.6	22
141	2-Butyl-4-chloroimidazole based substituted piperazine-thiosemicarbazone hybrids as potent inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5520-5524.	2.2	23
142	Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 605-613.	5.5	11
143	Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 71-78.	5.5	29
144	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: Pharmacophore mapping from known antibacterial leads. <i>European Journal of Medicinal Chemistry</i> , 2014, 85, 593-604.	5.5	9

#	ARTICLE	IF	CITATIONS
145	Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6134-6145.	3.0	9
146	Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5970-5987.	3.0	17
147	Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders. <i>Journal of Molecular Graphics and Modelling</i> , 2014, 52, 46-56.	2.4	20
148	Design, synthesis and anti-mycobacterial activity of 1,2,3,5-tetrasubstituted pyrrolyl-N-acetic acid derivatives. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 118-126.	5.5	17
149	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4924-4934.	3.0	47
150	Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4223-4232.	3.0	28
151	Multiple eâ€Pharmacophore Modeling Combined with Highâ€Throughput Virtual Screening and Docking to Identify Potential Inhibitors of Î²â€Secretase(BACE1). <i>Molecular Informatics</i> , 2013, 32, 385-398.	2.5	39
152	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies. <i>Medicinal Chemistry Research</i> , 2012, 21, 1451-1470.	2.4	58
153	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides. <i>Medicinal Chemistry Research</i> , 2012, 21, 1935-1952.	2.4	40
154	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives. <i>Medicinal Chemistry Research</i> , 2012, 21, 1557-1576.	2.4	54
155	Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5149-5154.	2.2	25
156	Aromatic amino analogues of artemisinin: synthesis and in vivo antimalarial activity. <i>Medicinal Chemistry Research</i> , 2010, 19, 524-532.	2.4	8
157	5-Nitro-2-furoic acid hydrazones: Design, synthesis and in vitro antimycobacterial evaluation against log and starved phase cultures. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4313-4316.	2.2	41
158	Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 120-123.	5.5	27
159	5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, <i>in vitro</i> antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2010, 25, 765-772.	5.2	14
160	Efavirenz Mannich bases: Synthesis, anti-HIV and antitubercular activities. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2009, 24, 1-5.	5.2	34
161	5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1152-1154.	2.2	40
162	Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 36-39.	5.6	20

#	ARTICLE	IF	CITATIONS
163	Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2009, 24, 1-5.	5.2	8
164	Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 1-5.	5.6	7
165	Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1194-1196.	3.0	62
166	Antimycobacterial Activities of Novel 1-(Cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic Acid. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6232-6239.	6.4	37
167	N-Hydroxythiosemicarbazones: Synthesis and in vitro antitubercular activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1888-1891.	2.2	23
168	Newer tetracycline derivatives: Synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2372-2375.	2.2	37
169	Evaluation of antimycobacterial and DNA gyrase inhibition of fluoroquinolone derivatives. <i>Journal of General and Applied Microbiology</i> , 2006, 52, 195-200.	0.7	12
170	Abacavir prodrugs: Microwave-assisted synthesis and their evaluation of anti-HIV activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2127-2129.	2.2	142
171	Synthesis of pyrazinamide Mannich bases and its antitubercular properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2113-2116.	2.2	52
172	Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of <i>Mycobacterium tuberculosis</i> DNA gyrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2982-2985.	2.2	103
173	Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3113-3118.	3.0	89
174	Discovery of New Antitubercular Oxazolyl Thiosemicarbazones. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3448-3450.	6.4	92
175	Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-[1-[(pyridine-4-carbonyl)hydrazono]ethyl]phenyl)thiourea. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 876-878.	2.2	74
176	Heteroaryl-substituted semicarbazones: Synthesis and anticonvulsant activity of N-(3-methylpyridin-2-yl)-substituted semicarbazones. <i>Journal of Heterocyclic Chemistry</i> , 2006, 43, 1287-1293.	2.6	1
177	Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5774-5778.	3.0	115
178	Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4502-4505.	2.2	129
179	Camptothecin and its analogues: a review on their chemotherapeutic potential. <i>Natural Product Research</i> , 2005, 19, 393-412.	1.8	125
180	Synthesis, Antiviral and Antibacterial Activities of Isatin Mannich Bases. <i>Medicinal Chemistry Research</i> , 2005, 14, 211-228.	2.4	43

#	ARTICLE	IF	CITATIONS
181	Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, 456-459.	5.6	6
182	Aminopyrimidinimino Isatin Analogues: Design and Synthesis of Novel Non- Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Broad- Spectrum Anti-Microbial Properties. <i>Medicinal Chemistry</i> , 2005, 1, 277-285.	1.5	9
183	Microwave-assisted synthesis and anti-YFV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 426-9.	2.1	4
184	Aminopyrimidinimino isatin analogues: design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 565-77.	2.1	32
185	Antituberculous activity of some aryl semicarbazone derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3923-3924.	2.2	37
186	Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 5865-5873.	3.0	53
187	Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 1085-1087.	2.2	32
188	Progress in the research of artemisinin and its analogues as antimalarials: an update. <i>Natural Product Research</i> , 2004, 18, 503-527.	1.8	46
189	Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS. <i>Current Medicinal Chemistry</i> , 2003, 10, 1689-1695.	2.4	26